The expression of Beta Human Chorionic Gonadotrophin (β-HCG) in human urothelial carcinoma
2010

Beta-HCG Expression in Bladder Cancer

Sample size: 86 publication Evidence: moderate

Author Information

Author(s): Anthony Kodzo-Grey Venyo, David Herring, Harold Greenwood, Douglas John Lindsay Maloney

Primary Institution: North Manchester General Hospital

Hypothesis

The expression of β-HCG in urothelial cancer is more commonly associated with tumours of high grade and high category and that the expression of β-HCG is associated with inferior outcome.

Conclusion

The expression of β-HCG can predict which superficial tumours will recur and which muscle-invasive tumours will have a poor outcome.

Supporting Evidence

  • 33 of the 86 tumours (38%) were positive for β-HCG.
  • Positive staining was more common in higher grade tumours.
  • Only 1 of the 20 patients with β-HCG positive muscle invasive tumours survived.

Takeaway

This study found that bladder cancer tumours that test positive for a substance called β-HCG are more likely to come back after treatment and are often more aggressive.

Methodology

The study analyzed the expression of β-HCG in urothelial carcinomas of 86 patients using immunohistochemistry.

Limitations

The study had a small sample size and did not consider nodal involvement in muscle-invasive tumours.

Participant Demographics

86 patients (49 male, 37 female), mean age 69.5 years (range 20 to 95 years).

Statistical Information

P-Value

p < 0.01

Statistical Significance

p < 0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication